Immunomodulatory therapies delay disease progression in multiple sclerosis
The DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background Few studies have analysed long-term effects of immunomodulatory disease modifying drugs (DMDs). Objective Assessment of the efficacy of DMDs on long-term evolution of multiple sclerosis, using a Bayesian approach to overcome methodological problems related to open-label studies. Methods MS patients from three different Italian multiple sclerosis centres were divided into subgroups according to the presence of treatment in their disease history before the endpoint, which was represented by secondary progression. Patients were stratified on the basis of the risk score BREMS (Bayesian risk estimate for multiple sclerosis), which is able to predict the unfavourable long-term evolution of MS at an early stage. Results We analysed data from 1178 patients with a relapsing form of multiple sclerosis at onset and at least 10 years of disease duration, treated (59%) or untreated with DMDs. The risk of secondary progression was significantly lower in patients treated with DMDs, regardless of the initial prognosis predicted by BREMS. Conclusions DMDs significantly reduce the risk of multiple sclerosis progression both in patients with initial high-risk and patients with initial low-risk. These findings reinforce the role of DMDs in modifying the natural course of the disease, suggesting that they have a positive effect not only on the inflammatory but also on the neurodegenerative process. The study also confirms the capability of the BREMS score to predict MS evolution.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“currently used immunomodulatory and immunosuppressive treatments are modestly or not effective in the secondary progressive phase of the disease but may delay the onset of the secondary progressive phase when used early in the inflammatory relapsing phase [281]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [281]
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., Haas, T., Korn, A. A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,054
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 681
Comi, G., Martinelli, V, Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H., Hillert, J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61259-9 · Cited by 592
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.003 · Cited by 549
Spiegelhalter, D. J., Myles, J. P., Jones, D. R., & Abrams, K. R. (1999) · BMJ · doi:10.1136/bmj.319.7208.508 · Cited by 421
New natural history of interferon‐β–treated relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G. B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21102 · Cited by 270
Self-citationLanger-Gould, A., Popat, R. A., Huang, S. M., Cobb, K., Fontoura, P., Gould, M. K., & Nelson, L. M. (2006) · Archives of Neurology · doi:10.1001/archneur.63.12.1686 · Cited by 229
Natural history of secondary-progressive multiple sclerosis
Tremlett, H., Zhao, Y., & Devonshire, V. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507084264 · Cited by 217
IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event
CHAMPIONS Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000200778.65597.ae · Cited by 203
For Debate: The statistical basis of public policy: a paradigm shift is overdue
Lilford, R. J., & Braunholtz, D. (1996) · BMJ · doi:10.1136/bmj.313.7057.603 · Cited by 188
The natural history of multiple sclerosis: a geographically based study
Kremenchutzky, M., Cottrell, D., Rice, G., Hader, W., Baskerville, J., Koopman, W., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.10.1941 · Cited by 186
IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event
Goodin, D. S. (2006) · Neurology · doi:10.1212/01.wnl.0000240402.04846.6d · Cited by 186
Disability as an outcome in MS clinical trials
Ebers, G. C., Heigenhauser, L., Daumer, M., Lederer, C., & Noseworthy, J. H. (2008) · Neurology · doi:10.1212/01.wnl.0000313034.46883.16 · Cited by 180
Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G. B., Tortorella, C., Simone, I. L., Patti, F., Ghezzi, A., Zipoli, V., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21757 · Cited by 148
Self-citationPredicting secondary progression in relapsing–remitting multiple sclerosis: a Bayesian analysis
Bergamaschi, R., Berzuini, C., Romani, A., & Cosi, V. E. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00572-x · Cited by 147
Self-citationFord, C. C., Johnson, K. P., Lisak, R. P., Panitch, H. S., Shifroni, G., Wolinsky, J. S., & The Copaxone® Study Group (2006) · Multiple Sclerosis Journal · doi:10.1191/135248506ms1318oa · Cited by 138
Ebers, G. C., Traboulsee, A. L., Li, D., Langdon, D. W., Reder, A. T., Goodin, D. S., Bogumil, T., Beckmann, K., Wolf, C., Konieczny, A., et al. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.204123 · Cited by 137
Multiple sclerosis risk sharing scheme: a costly failure
Raftery, J. (2010) · BMJ · doi:10.1136/bmj.c1672 · Cited by 86
Goodin, D., & Bates, D. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509107007 · Cited by 84
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown, M. G., Kirby, S. E., Skedgel, C. D., Fisk, J. D., Murray, T. J., Bhan, V., & SKETRIS, I. S. (2007) · Neurology · doi:10.1212/01.wnl.0000271884.11129.f3 · Cited by 83
Bergamaschi, R. C., Quaglini, S., Trojano, M., Amato, M. P., Tavazzi, E., Paolicelli, D., Zipoli, V., Romani, A., Fuiani, A., Portaccio, E., et al. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.107052 · Cited by 78
Self-citationMilanese, C. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.12.1689 · Cited by 70
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
Rudick, R. A., Cutter, G., Baier, M. L., Weinstock‐Guttman, B., Mass, M. K., Fisher, E., Miller, D. M., & Sandrock, A. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1203oa · Cited by 66
Berzuini, C., & Larizza, C. (1996) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/34.481537 · Cited by 45
Bergamaschi, R. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.3.357 · Cited by 33
Self-citationQuality assurance in non-interventional studies
Theobald, K., Capan, M., Herbold, M., Schinzel, S., & Hundt, F. (2009) · PubMed Central · doi:10.3205/000088 · Cited by 32
Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?
Trojano, M. (2007) · Neurology · doi:10.1212/01.wnl.0000275545.08382.82 · Cited by 28
Self-citationThe search for a balance between short and long-term treatment outcomes in multiple sclerosis
Baumhackl, U. (2008) · Journal of Neurology · doi:10.1007/s00415-008-1010-8 · Cited by 10
Research works printed but not linked: 4
- IFNB Multiple Sclerosis Study Group, 2001, Neurology, 57, S3
- Johnson KP, 2001, Neurology, 57, S16
- Theobald K, 2009, Ger Med Sci, 7
- Berzuini C, 1996, IEEE Trans Patt Anal Machine Intell, 2, 109-110
Cited by
Brown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Trojano, M., Lugaresi, A., et al. (2019) · JAMA · doi:10.1001/jama.2018.20588 · Cited by 546
Self-citationAgeing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“In line with our hypothesis, currently used immunomodulatory and immunosuppressive treatments are modestly or not effective in the secondary progressive phase of the disease but may delay the onset of the secondary progressive phase when used early in the inflammatory relapsing phase [281], probably due to their effic…”
ResultTreatment Optimization in MS: Canadian MS Working Group Updated Recommendations
Freedman, M. S., Selchen, D., Arnold, D. L., Prat, A., Banwell, B., Yeung, M., Morgenthau, D., & Lapierre, Y. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100014244 · Cited by 202
Treatment decisions in multiple sclerosis — insights from real-world observational studies
Trojano, M., Tintore, M., Montalban, X., Hillert, J., Kalincik, T., Iaffaldano, P., Spelman, T., Sormani, M. P., & Butzkueven, H. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.188 · Cited by 191
Self-citationThe Italian multiple sclerosis register
Trojano, M., Bergamaschi, R., Amato, M. P., Comı, G., Ghezzi, A., Lepore, V. L., Marrosu, M. G., Mosconi, P., Patti, F., Ponzio, M., et al. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3610-0 · Cited by 107
Self-citation
Metadata
- Authors
- Bergamaschi, R., Quaglini, S., Tavazzi, E., Amato, M. P., Paolicelli, D., Zipoli, V., Romani, A., Tortorella, C., Portaccio, E., D’Onghia, M., Garberi, F., Bargiggia, V., & Trojano, M.
- Affiliations
- Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
- University of Pavia (IT)
- University of Florence (IT)
- University of Bari Aldo Moro (IT)
- Department of Neurological and Psychiatric Sciences, University of Bari, Italy
- Corresponding author
- Bergamaschi, Roberto
- ORCID
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2016-07-20
- Volume
- 22
- Issue
- 13
- Pages
- 1732-1740
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2055317435
- Cited by
- 71
- References
- 38
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 8 · 2019: 11 · 2018: 3 · 2017: 2 · 2016: 4
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Multiple Sclerosis Journal (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- multiple sclerosis, disease-modifying drugs, immunomodulatory therapy, relapsing multiple sclerosis, Bayesian risk estimation, long-term disease course, neurodegeneration, treatment response prediction
- MeSH terms
- Adult, Female, Follow-Up Studies, Humans, Immunotherapy, Male, Middle Aged, Prognosis, Severity of Illness Index, Outcome Assessment, Health Care, Disease Progression, Multiple Sclerosis, Relapsing-Remitting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.